Hannover / Germany, – ZELLKRAFTWERK today announced the start of its early technology access program for ChipcytometryTM, a groundbreaking high-content cytometry technology for cellular biomarker discovery and bioanalysis. ChipcytometryTM allows for sample storage and biomarker preservation for about 12 month and enables iterative re-analysis of the same sample with different marker-sets for several times. In a constantly growing number of studies, ChipcytometryTM has been validated for a broad range of clinical specimens and has delivered excellent results published in high rank journals.

Pharmaceutical researchers in many disease areas currently have high interest in revealing correlations between biomarker expression and signaling pathway activity directly on cells from tissues and body fluids and the respective patient outcome. ChipcytometryTM is an extremely powerful tool for cellular biomarker discovery in the field of drug development and uses proprietary technology to make life science research and drug and diagnostic development programs safer, more efficient and effective. Whether measuring dozens of biomarkers or simply a few, our approach provides reproducible, quantitative, sensitive immunophenotyping data from a small sample volume.

ZELLKRAFTWERKs early technology access program now makes ChipcytometryTM available to researchers and drug developers worldwide. Under this program ZELLKRAFTWERK will work with academic institutions and biotech companies in specific disease areas on an exclusive basis to identify new drug target and new efficacy and safety biomarkers.

Since 2008, Dr. Christian Hennig and his team has used ChipcytometryTM in a growing number of preclinical and clinical applications and has published excellent results in high rank peer-reviewed journals. ‘The massive multiplexing capability really sets ChipcytometryTM apart from conventional flow cytometry‘ states Christian Hennig, CEO and co-founder of ZELLKRAFTWERK. ‘For the first time ChipcytometryTM allows researchers to use an iterative ‘stain-think-stain’-approach for biomarker discovery. It’s really like you are communicating with your cells‘ he adds.

About ChipcytometryTM:

The ChipcytometryTM technology platform provides hardware and software for explorative cytometry. It differentiates itself from flowcytometry by keeping cells immobilized inside a microfluidic-channel allowing the stepwise, quantitative analysis of biomarkers on cells and tissues using a flexible and literally unlimited set of markers. ChipcytometryTM has been developed by a team of researchers at Hannover Medical School. The project is funded by Federal Ministry of Education and Research (Germany) under the GOBio program.

The platform is compatible to a broad range of biomarker types (baseline, activity, and functionality biomarkers) and allows for multiplexing of up to 30 biomarkers per sample in an iterative workflow. ChipcytometryTM has shown a 10-fold better sensitivity compared to flowcytometry. Sample- and cellular biomarker stability has been validated for 12 month when cells are stored inside their proprietary microfluidic chips. The ChipcytometryTM platform recently has been validated for clinical use in a number of biomarker discovery projects with institutions like MD Anderson Cancer Center, Houston, German Competence Network Multiple Sclerosis, the German Center for Lung Research and the Radboud University, Nijmegen.